Home > Neurology > EAN 2021 > Parkinson’s Disease > Safinamide improves non-motor symptoms in PD

Safinamide improves non-motor symptoms in PD

Conference
EAN 2021
Trial
SAFINONMOTOR
An open-label study confirmed previously observed beneficial effects of safinamide on non-motor symptoms of Parkinson’s disease (PD). Safinamide was well tolerated and improved both non-motor symptom burden and quality of life (QoL) in PD patients after 6 months. Safinamide is a new monoamine oxidase (MAO) B inhibitor which also exerts a non-dopaminergic effect. The SAFINONMOTOR trial is a prospective, open-label, single-arm study to assess the effectiveness of safinamide on non-motor symptoms in PD patients [1]. The study's primary endpoint is change from baseline (V1) after 6 months (V4) in the Non-Motor Symptoms Scale (NMSS) total score. A total of 50 PD patients were included. Median age was 68.5; 58% were women; they had been diagnosed a mean of 6.4 years before. A total of 44 (88%) completed the follow-up observational period of 6 months. The NMSS total score was reduced by 38.5% (P<0.0001) after 6 months: at baseline, it was 97.5; after 1 ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on